Clinical trials: Post Discharge
Adult Patients With Type 2 Diabetes Mellitus
XIGDUO Extended Release (XR) Post Marketing Surveillance
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. Adult patients with type 2 diabetes mellitus who are initiating Xigduo XR as indicated by the Ministry of Food and Drug Safety (MFDS)…
- Trial name
- XigduoPMS (NCT03038789)
- Where
- 8 sites in South Korea
- Volunteers
- 623 people
- Sponsor
- AstraZeneca
Healthy
Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.
Bioequivalence study of quetiapine in healthy volunteers, comparing the test extended release formulation, Kemoter XR with respect to the reference product, Etiasel XR ® from AstraZeneca S.A., under a single-dose, two-way…
- Trial name
- NCT03317236
- Testing
- Quetiapine
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Heart Failure With Reduced Ejection Fraction
Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.
- Trial name
- TRANSITION (NCT02661217)
- Testing
- LCZ696
- Where
- 152 sites in Argentina, Belgium and 17 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
- Trial name
- NCT00564954
- Testing
- Dex-methylphenidate hydrochloride extended-release (Focalin XR)
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Women
Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women
The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following single oral doses of three modified-release (MR)…
- Trial name
- NCT02112903
- Testing
- Encapsulated vortioxetine IR tablet, 20 mg, Vortioxetine MR capsule 20 mg (pH 5.5), Vortioxetine MR capsule 20 mg (pH 6.0)
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Heart Failure
Implementation for Heart Failure Therapies Post-discharge Followed by CardiOSIgnal at HOME
CardioSignal technology (mechanocardiography) could enable home follow-up after admission for acute heart failure, thus improving guidline-directed medical therapies for heart failure dose escalation while reducing the logistical…
- Trial name
- COSI-HOME (NCT06944405)
- Testing
- Mechanocardiography
- Where
- 2 sites in Tunisia
- Volunteers
- 65 people
- Sponsor
- Precordior Ltd
Neuropathy;Peripheral
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
- Trial name
- SELECT (NCT05980767)
- Testing
- Temporary Peripheral Nerve Stimulation System
- Where
- 2 sites in Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Epineuron Technologies Inc.
Post-Operative Pain, Third Molar Extraction
Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction
This study involves approximately 200 patients designed to evaluate the efficacy and safety of intranasal (IN) morphine 7.5 mg and 15 mg, intravenous morphine (IV) 7.5 mg, immediate release oral (PO) morphine 60 mg or placebo in…
- Trial name
- NCT00390312
- Testing
- Intranasal Morphine 15 mg, Immediate Release Oral Morphine 60 mg, Intravenous morphine
- Volunteers
- 225 people
- Sponsor
- Javelin Pharmaceuticals
Parkinson's Disease
To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers
To evaluate the pharmacokinetics of AZD3241 following multiple administration of 2 new, different extended release formulations of tablets of AZD3241 (300 mg), in relation to the 100 mg extended release tablet used in a previous…
- Trial name
- NCT01457807
- Testing
- AZD3241 ER formulation 1, AZD3241 Alternative titration scheme with formulation 1 or 2
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients
This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.
- Trial name
- VISOR (NCT03255512)
- Testing
- Vericiguat (BAY1021189), Isosorbide mononitrate (ISMN)
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Bayer
Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
- Trial name
- NCT00415597
- Testing
- ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- Where
- 58 sites in United States
- Volunteers
- 467 people
- Sponsor
- Pfizer
Post-ischemic Stroke
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
- Trial name
- MILESTONE℠ (NCT02422940)
- Testing
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Where
- 66 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Acorda Therapeutics
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
- Trial name
- NCT00683332
- Testing
- Tigecycline (Tygacil)
- Where
- Philippines
- Volunteers
- 621 people
- Sponsor
- Pfizer
Pulmonary Fistula
Investigation of an Adaptive Treatment Algorithm for Post-op Thoracic Patients to Reduce the Length of Drainage
The purpose of this study is to reduce the length of drainage using a treatment protocol to control the manipulation of the applied vacuum to the pleural cavity.
- Trial name
- AATD (NCT01177215)
- Testing
- Thoracic Surgery
- Where
- 4 sites in Germany
- Volunteers
- 39 people
- Sponsor
- Medela AG
Lymphorrhea
Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea
This is a phase II, multicenter, double-blind, double-dummy, parallel-group, placebo-controlled, study to evaluate LF-PB versus placebo in female patients with brest cancer who are undergoing breast surgery with axillary…
- Trial name
- NCT01754285
- Testing
- LF-PB
- Where
- 13 sites in Italy
- Volunteers
- 114 people
- Sponsor
- Chemi S.p.A.
Sinusitis
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
- Trial name
- NCT00232154
- Testing
- Zithromax™ (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology
- Where
- 18 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer
Primary Open Angle Glaucoma
Post Market Study of the InnFocus MicroShunt
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
- Trial name
- NCT02177123
- Testing
- InnFocus MicroShunt implantation
- Where
- 6 sites in France, Netherlands and 2 more
- Volunteers
- 107 people
- Sponsor
- InnFocus Inc.
Aortic Valve Stenosis, Aortic Valve Insufficiency
Enable® Aortic Sutureless Bioprosthesis Evaluation
The EASE Enable study is intended to collect additional data on the clinical outcomes of the Medtronic Enable® Aortic Bioprosthesis in "real world" patients.
- Trial name
- EASE (NCT01720342)
- Testing
- Aortic Valve Replacement surgery
- Where
- 17 sites in France, Germany and 5 more
- Volunteers
- 225 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Diabetes
Diabetes Multicenter Observational Study (DIAMOND-1-)
The purpose of this study is to examine whether pump treatment combined with the use of continuous glucose monitoring system is a mena to normalize glycaemic control.
- Trial name
- DIAMOND-1 (NCT01369823)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medtronic Hellas Medical Devices ΑEE